NCT03737604 TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
| NCT ID | NCT03737604 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, Davis |
| Condition | Transplant;Failure,Kidney |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2018-10-04 |
| Primary Completion | 2026-06-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 200 participants in total. It began in 2018-10-04 with a primary completion date of 2026-06-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a comparison of the analgesic efficacy of transversus abdominis plane (TAP) blocks with ropivacaine bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with liposomal bupivacaine.
Eligibility Criteria
Inclusion Criteria: * Patients ages 18 years or older * Renal Transplant Recipients Exclusion Criteria: * Patients less than 18 years of age * Pregnant Women * Prisoners * Opioid Tolerant Patients taking more than 30 mg/day of oral morphine equivalent analgesia * Patients on Systemic anti coagulation * Patients unable to provide consent * Hypersensitivity to amide-type local anesthetic or any component of the drug formula
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03737604 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Transplant;Failure,Kidney. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03737604 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03737604 currently recruiting?
Yes, NCT03737604 is actively recruiting participants. Contact the research team at apaarias@ucdavis.edu for enrollment information.
Where is the NCT03737604 trial being conducted?
This trial is being conducted at Sacramento, United States.
Who is sponsoring the NCT03737604 clinical trial?
NCT03737604 is sponsored by University of California, Davis. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.